Aust Fam Physician
-
Vaccine hesitancy is a public health concern. The objectives of this article were to describe Australian parents' attitudes, behaviours and concerns about vaccination, determine the factors associated with vaccination non-compliance, and provide sources of vaccination information for general practitioners (GPs). ⋯ The 452 respondents were parents of children aged DISCUSSION: GPs have pivotal roles in addressing concerns regarding vaccination. Education and communication with parents will improve their knowledge and trust in vaccination, thereby improving vaccination compliance.
-
More than a trillion, mostly good, microbes live within our gastrointestinal tract and are responsible for vital metabolic, immune and nutritional functions. Dysbiosis, meaning a maladaptive imbalance of the microbiome, is associated with many common diseases and is a target for therapy. ⋯ As our knowledge of the microbiome increases, we are likely to better understand the complex interactions that cause disease, and develop new and more effective treatments for many common conditions.
-
Scabies is a common, yet neglected, skin disease. Scabies occurs across Australia, but most frequently in socioeconomically disadvantaged populations in tropical regions, including in remote Aboriginal and Torres Strait Islander communities. In temperate settings, the disease clusters in institutional care facilities. ⋯ Clinical examination remains the mainstay of diagnosis, although dermatoscopy is a useful adjunct. Scabies presents with severe itch and a papular rash, with a predilection for the hands, feet and genitalia. The distribution may be more widespread in infants and older people. Secondary bacterial infection is also common in patients with scabies. Crusted scabies is a rare but highly infectious variant. Topical permethrin is highly effective for individual treatment, but less practical for treatment of asymptomatic contacts and control of outbreaks. Oral ivermectin is a safe and effective alternative, and is now listed on the Pharmaceutical Benefits Scheme as a third-line treatment.